About Hypha Discovery

Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide by producing metabolites and new derivatives of drugs and agrochemicals in discovery and development. Hypha is an expert in the scalable synthesis of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the production, purification and structure elucidation of natural products.

NEW PolyCYPs®+ biocatalysis kits

PolyCYPs®+ is a new product comprising more than double the number of CYPs contained in the original kit, and broadened by the addition of other phase I enzymes. Human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3) are now included in the kit, with other human FMO isoforms available soon. Inclusion of new PolyCYPs isoforms broadens coverage of reactions, and have been proven to metabolise some low turnover drugs and produce multi-step oxidised metabolites.

Download an info sheet on PolyCYPs+

Click here to find out more about PolyCYPs+ kits

NEWS & EVENTS

WEBINARS – Thursday 5th December

Join one of our webinars on “New tools for metabolite synthesis: enhanced PolyCYPs+ kit and late-stage chemical glucuronidation” on Thursday 5th December.

Come and meet us at the following events

Synthetic Biology UK 2019

9th – 10th December 2019, University of Warwick, UK

Vincent Poon, Hypha’s Senior Molecular Biologist, will be presenting a poster on “Improvement of PolyCYPs® microbial cytochrome P450 cell factory for efficient whole-cell biotransformation” joint with collaborating scientists at University College London

SCI/RSC Applied Late-stage Functionalisation: Where Chemistry meets Biology

18th – 19th February 2020, Manchester, UK

Hypha will be giving a talk on LSF using PolyCYPs enzymes

Hypha’s latest metabolite project update

Hypha’s PolyCYPs enzymes have been routinely used by pharma and agchem companies for producing metabolites. One application involves direct comparison of radiometric profiles of PolyCYPs and regulatory study samples. In this study by Charles River, a radiolabelled agrochemical compound was incubated with PolyCYPs and the metabolites matched with those detected in goat faeces, as part of an mass balance and disposition study, thereby providing an immediate route to access and scale-up metabolites. Click here for a link to an illustration of the results of this study.

Download a copy of our brochure on drug metabolites and C-H activated derivatives

Drug metabolites and C-H activated derivatives brochure

Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:

Phase l CYP and non-CYP metabolites
Phase ll conjugated metabolites such as glucuronides and sulfates
Isotopically labelled metabolites
Lead diversification / late stage functionalization
Production of polar derivatives of drug lead compounds

Download a copy here

Recent Publication

Let us know if you would like a copy of a paper published last year in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d

Glucuronide Synthesis

In a recent newsletter we described a case study illustrating the use of microbial biotransformation to produce scalable quantities of glucuronides, focusing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs.

Access a pdf of the newsletter on glucuronides of carboxylic acid-containing drugs